title: Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.
abstract: Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implications are discussed.
authors.affiliation: Division of Cardiovascular Medicine, Harvard-Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215-3908, USA. rverrier@bidmc.harvard.edu
authors.forename: Richard L
authors.initials: RL
authors.lastname: Verrier
authors.forename: Kapil
authors.initials: K
authors.lastname: Kumar
authors.forename: Tuomo
authors.initials: T
authors.lastname: Nieminen
authors.forename: Luiz
authors.initials: L
authors.lastname: Belardinelli
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D000200:Action Potentials; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010879:Piperazines / Q000627:therapeutic use*; D000069458:Ranolazine; D012964:Sodium / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D000083:Acetanilides; D000889:Anti-Arrhythmia Agents; D010879:Piperazines; D026941:Sodium Channel Blockers; D012964:Sodium; D000069458:Ranolazine